Chemotherapy News and Research

Latest Chemotherapy News and Research

MRI provides early indication of breast tumor's response to pre-surgical chemotherapy

Magnetic resonance imaging (MRI) provides an indication of a breast tumor's response to pre-surgical chemotherapy significantly earlier than possible through clinical examination, according to a new study published online in the journal Radiology.

23 May 2012

Prodigy Generics launches injectable irinotecan

Prodigy Generics, a division of Prodigy Health Supplier Corporation (PHS), has launched injectable irinotecan. Irinotecan is the generic equivalent of the branded drug Camptosar by Pfizer.

23 May 2012

Diamyd Medical completes enrollment in NP2 Enkephalin Phase II study for cancer pain

The last study participant has been recruited to Diamyd Medical's Phase II study in which cancer pain is treated with the drug candidate NP2 Enkephalin. The study is thus fully enrolled and results are expected to be reported in five to seven weeks.

22 May 2012

HSF-1 protein likely source of chemotherapy-related heart damage in mice

Blocking a protein in the heart that is produced under stressful conditions could be a strategy to prevent cardiac damage that results from chemotherapy, a new study suggests.

22 May 2012

New strategy can reactivate genes that cause cancer tumors to shrink and die

A team of scientists has developed a promising new strategy for "reactivating" genes that cause cancer tumors to shrink and die. The researchers hope that their discovery will aid in the development of an innovative anti-cancer drug that effectively targets unhealthy, cancerous tissue without damaging healthy, non-cancerous tissue and vital organs.

22 May 2012

MGH develops new technique to reconstruct the larynx after surgery for advanced cancer

Massachusetts General Hospital (MGH) surgeons have developed a new technique for reconstructing the larynx after surgery for advanced cancer.

22 May 2012

New therapeutic options for management of melanoma brain metastases

In a recent article published in MELANOMA RESEARCH and a subsequent commentary in British medical journal THE LANCET, researchers at Moffitt Cancer Center discussed new therapeutic options for the management of melanoma brain metastases. Patients with advanced melanoma are at high risk for developing brain metastases. Once brain metastases are present, these patients tend to have poor outcomes.

21 May 2012

TTFields therapy vs. chemotherapy in patients with recurrent glioblastoma

Results of the first randomized controlled trial to compare a novel cancer treatment modality delivering Tumor Treating Fields (TTFields) therapy versus chemotherapy in patients with recurrent glioblastoma (GBM) were published in the European Journal of Cancer.

21 May 2012

Deletion of 'lunatic fringe' promotes tumor formation of basal-like breast cancers

Multiple research projects - including a 2006 study conducted at the University of North Carolina at Chapel Hill - have used DNA microarray analysis to identify several breast cancer subtypes, including luminal A, luminal B, basal-like and HER2-enriched.

21 May 2012

Study identifies biomarkers that predict patients' response to certain colon cancer drugs

The Stem Cells and Cancer Research Group headed by Dr H-ctor G. Palmer at the Vall d'Hebr-n Institute of Oncology (VHIO) has identified the molecular mechanisms that determine patients' response to certain drugs used in clinical trials for colon cancer treatment. The study led by VHIO also benefited from the collaboration with Professor Alberto Mu-oz-s laboratory at the Instituto de Investigaciones Biomedicas Alberto Sols, Consejo Superior de Investigaciones Cient-ficas.

21 May 2012

Panobinostat able to target and destroy triple negative breast cancer

The histone de-acetylase (HDAC) inhibitor panobinostat is able to target and destroy triple negative breast cancer, reveals a new study published in BioMed Central's open access journal Breast Cancer Research.

21 May 2012

Mount Sinai cancer researchers to present several landmark studies at ASCO meeting

Mount Sinai School of Medicine researchers will present several landmark studies, including data on treatment trends in late-stage cancer, a promising multiple myeloma vaccine, and predictive models of soft tissue sarcomas, prostate and bladder cancer, at the 2012 American Society of Clinical Oncology (ASCO) meeting June 1-5, 2012 in Chicago.

19 May 2012

Promising updates in quest for early detection and treatments for lung cancer

LUNGevity Foundation, the nation's largest lung cancer-focused nonprofit, is pleased to note promising updates in researchers' quest for early detection and treatments for lung cancer during May, Lung Cancer Hope Month.

18 May 2012

Ipsen, Active Biotech to present data from tasquinimod phase II trial on CRPC at ASCO 2012

Active Biotech and Ipsen will present tasquinimod (TASQ), their prostate cancer drug candidate, at the scientific conference "2012 ASCO Annual Meeting" to be held in Chicago (USA) on 1-5 June 2012.

18 May 2012

MSRG researchers develop ColoREctal Wellbeing study

Researchers from the Macmillan Survivorship Research Group (MSRG), at the University of Southampton, have developed the first study of its kind looking at the experiences and needs of people after primary treatment of colorectal cancer.

18 May 2012

Patients with muscle-invasive bladder cancer benefit from accelerated MVAC

For some patients with muscle-invasive bladder cancer, treatment may begin before they undergo cystectomy, or surgical removal of the bladder. They may be advised by oncologists to receive chemotherapy before surgery. A large randomized clinical trial published in 2003 demonstrated a survival benefit for neoadjuvant, or pre-surgical, MVAC (methotrexate, vinblastine, doxorubicin and cisplatin) using a standard dose and schedule.

18 May 2012

Spectrum initiates ZEVALIN and MGd Phase 2 combination study in NHL

Spectrum Pharmaceuticals, a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced the initiation of a Phase 2 study evaluating ZEVALIN (ibritumomab tiuxetan) Injection for intravenous use + rituximab in combination with motexafin gadolinium (MGd) in patients with rituximab-refractory low-grade or follicular B-cell non-Hodgkin's lymphoma.

18 May 2012

Apigenin effective against human breast cancer

Apigenin, a natural substance found in grocery store produce aisles, shows promise as a non-toxic treatment for an aggressive form of human breast cancer, following a new study at the University of Missouri.

17 May 2012

High-throughput sequencing can detect early signs of leukemia relapse

A study led by researchers at Fred Hutchinson Cancer Research Center has found that a next-generation, high-speed DNA-decoding technology called high-throughput sequencing can detect the earliest signs of potential relapse in nearly twice the number of leukemia patients as compared to flow cytometry, the current gold standard for detecting minimal residual disease.

17 May 2012

Updated results from Amgen’s blinatumomab Phase 2 study on ALL

Amgen today announced updated results from a Phase 2 study that showed treatment with blinatumomab (AMG 103) helped achieve a high-rate of complete response (CR) in 72 percent of adult patients with relapsed or refractory B-precursor acute lymphoblastic leukemia (ALL) treated in the study.

17 May 2012